As proteolytic cleavage is an indispensable activation event for many of these substrates, ADAM17 has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis.
| Inventor | Institute |
|---|---|
| Carl Blobel | Hospital for Special Surgery |
| SKU: | 152533 |
|---|---|
| Product description: | ADAM17 (TACE/CD156b) has proved capable of cleaving epidermal growth factor receptor (EGFR) ligands, extracellular Notch1, cell-surface receptors, and adhesion molecules. As proteolytic cleavage is an indispensable activation event for many of these substrates, ADAM17 has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis. |
| Conjugation: | Unconjugated |
| Molecular weight: | ~100 kDa (mature form), ~120 kDa (pro-form) |
| Immunogen: | GST-cyto corresponding to the cytoplasmic domain of murine ADAM17 |
| Cat. #: | 152533 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell signaling and signal transduction;Metabolism;Neurobiology;Stem cell biology |
| Application: | WB |
| Target: | ADAM17 |
| Reactivity: | Mouse |
| Clone: | 17MOCYT |
| Host: | Rabbit |
| Class: | Polyclonal |
| Target background: | ADAM17 (TACE/CD156b) has proved capable of cleaving epidermal growth factor receptor (EGFR) ligands, extracellular Notch1, cell-surface receptors, and adhesion molecules. As proteolytic cleavage is an indispensable activation event for many of these substrates, ADAM17 has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1 mg/ml |
| Storage buffer: | Whole serum |
| Storage conditions: | -20° C |
| Shipping conditions: | Dry ice |
| References: |
Horiuchi et al. 2007. J Immunol. 179(5):2686-9. PMID: 17709479. Le Gall et al. 2010. J Cell Sci. 123(Pt 22):3913-22. PMID: 20980382. Maretzky et al. 2011. Nat Commun. 2:229. PMID: 21407195. Schlndorff et al. 2000. Biochem J. 347 Pt 1:131-8. PMID: 10727411. Zheng et al. 2002. J Biol Chem. 277(45):42463-70. PMID: 12207026. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151025 | Anti-Vascular endothelium [10] |
Key Info
Anti-Vascular endothelium [10]
|
View Tool | |||||||||||||||||||
| 151033 | Anti-HSVUL42 [13C9] |
Key Info
Anti-HSVUL42 [13C9]
|
View Tool | |||||||||||||||||||
| 151036 | Anti-ICAM1 [15.2] |
Key Info
Anti-ICAM1 [15.2]
|
View Tool | |||||||||||||||||||
| 151037 | Anti-Cdk1 [17 (A17)] |
Key Info
Anti-Cdk1 [17 (A17)]
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.